Teva Pharmaceutical Industries Limited Company Profile (NYSE:TEVA)

About Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Teva Pharmaceutical Industries Limited logoTeva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. Its specialty medicines business focuses on delivering a range of solutions to patients and providers through medicines, devices and services in various regions and markets around the world. Its specialty medicines business includes its core therapeutic areas of central nervous system (CNS) and respiratory medicines with a focus on asthma and chronic obstructive pulmonary disease. It also has specialty products in oncology, women's health and selected other areas.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: N/A
  • Symbol: NYSE:TEVA
  • CUSIP: N/A
  • Web: www.tevapharm.com
Capitalization:
  • Market Cap: $17.76984 billion
  • Outstanding Shares: 1,016,000,000
Average Prices:
  • 50 Day Moving Avg: $27.91
  • 200 Day Moving Avg: $31.10
  • 52 Week Range: $16.81 - $53.96
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 4.36
  • P/E Growth: -2.79
Sales & Book Value:
  • Annual Revenue: $23.37 billion
  • Price / Sales: 0.74
  • Book Value: $23.99 per share
  • Price / Book: 0.71
Dividend:
  • Annual Dividend: $1.16
  • Dividend Yield: 6.6%
Profitability:
  • EBIDTA: $7.42 billion
  • Net Margins: -25.18%
  • Return on Equity: 15.96%
  • Return on Assets: 5.31%
Debt:
  • Debt-to-Equity Ratio: 1.30%
  • Current Ratio: 0.94%
  • Quick Ratio: 0.61%
Misc:
  • Average Volume: 14.86 million shs.
  • Beta: 0.46
  • Short Ratio: 4.71
 

Frequently Asked Questions for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

What is Teva Pharmaceutical Industries Limited's stock symbol?

Teva Pharmaceutical Industries Limited trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

How often does Teva Pharmaceutical Industries Limited pay dividends? What is the dividend yield for Teva Pharmaceutical Industries Limited?

Teva Pharmaceutical Industries Limited announced a quarterly dividend on Monday, August 7th. Stockholders of record on Tuesday, August 29th will be paid a dividend of $0.085 per share on Thursday, September 14th. This represents a $0.34 annualized dividend and a dividend yield of 1.99%. The ex-dividend date of this dividend is Friday, August 25th. View Teva Pharmaceutical Industries Limited's Dividend History.

How were Teva Pharmaceutical Industries Limited's earnings last quarter?

Teva Pharmaceutical Industries Limited (NYSE:TEVA) posted its quarterly earnings results on Thursday, August, 3rd. The company reported $0.99 earnings per share for the quarter, missing the Zacks' consensus estimate of $1.06 by $0.07. The business earned $5.69 billion during the quarter, compared to analysts' expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. Teva Pharmaceutical Industries Limited's revenue for the quarter was up 12.9% compared to the same quarter last year. During the same quarter last year, the business posted $1.25 earnings per share. View Teva Pharmaceutical Industries Limited's Earnings History.

When will Teva Pharmaceutical Industries Limited make its next earnings announcement?

Teva Pharmaceutical Industries Limited is scheduled to release their next quarterly earnings announcement on Tuesday, November, 21st 2017. View Earnings Estimates for Teva Pharmaceutical Industries Limited.

What guidance has Teva Pharmaceutical Industries Limited issued on next quarter's earnings?

Teva Pharmaceutical Industries Limited updated its FY17 earnings guidance on Thursday, August, 3rd. The company provided earnings per share (EPS) guidance of $4.30-4.50 for the period, compared to the Thomson Reuters consensus estimate of $4.73. The company issued revenue guidance of $22.8-23.2 billion, compared to the consensus revenue estimate of $23.43 billion.

Where is Teva Pharmaceutical Industries Limited's stock going? Where will Teva Pharmaceutical Industries Limited's stock price be in 2017?

25 analysts have issued 12 month price objectives for Teva Pharmaceutical Industries Limited's shares. Their forecasts range from $19.00 to $80.00. On average, they anticipate Teva Pharmaceutical Industries Limited's share price to reach $36.82 in the next year. View Analyst Ratings for Teva Pharmaceutical Industries Limited.

What are analysts saying about Teva Pharmaceutical Industries Limited stock?

Here are some recent quotes from research analysts about Teva Pharmaceutical Industries Limited stock:

  • 1. According to Zacks Investment Research, "Teva missed estimates for both earnings and sales in Q2. The company also slashed its 2017 earnings and sales outlook to reflect the challenging environment in the U.S. generics business and the continued deterioration in Venezuela. Teva also announced a 75% cut in its dividend. The U.S. generics industry’s competitive and pricing pressure is expected to continue in the near future. Teva is facing several other challenges in the form of generic competition for Copaxone, new competition for branded products, a high cost base and debt load and the sudden departure of its CEO. Also, Teva’s shares underperformed the generic industry this year so far. Nonetheless, Teva is progressing with its branded/generics drugs pipeline and is looking to strengthen its biosimilar pipeline. The Actavis Generics acquisition is contributing to the growth of the Generics unit. However, a clear path to growth is not visible." (8/9/2017)
  • 2. Jefferies Group LLC analysts commented, "MDCO announced early stoppage of the Ph 3 TANGO-2 trial for Vabomere (Carbavance) based on an interim analysis which showed a superior benefit-risk compared to best available therapy in serious infections due to CRE. We are impressed by DSMB stoppage of a trial with less than half of patients enrolled (72 out of the 150 target) suggesting a dramatic clinical benefit vs. standard of care. We believe today’s news provides a favorable setup for the August 21 (our estimate) PDUFA for Vabomere in cUTI. We continue to see Vabomere as a potential source of optionality for MDCO should management decide to launch this important new antibiotic on their own or in conjunction with a partner." (7/25/2017)
  • 3. Maxim Group analysts commented, "We reviewed and revised our model prior to the 1Q17 earnings release. Based on 2017 guidance and our expectations, we adjust OTC revenues in 1Q17 to $277M from $346M to reflect the change in foreign exchange rate as of December 1, 2016. Our estimate for total 2017 revenues is unchanged at $24B." (3/29/2017)
  • 4. Royal Bank Of Canada analysts commented, "TEVA reported 4Q above Street expectations and reaffirmed 2017 guidance with some further color around the year. The bull case in TEVA lacks conviction and change is needed. We look to CEO search/ strategic review, potential for break-up, and potential upside from generic Copaxone surprise as opportunity but near-term confidence remains low. No change to PT but EPS moves lower to reflect greater competitive pressures." (2/14/2017)

Are investors shorting Teva Pharmaceutical Industries Limited?

Teva Pharmaceutical Industries Limited saw a increase in short interest in July. As of July 31st, there was short interest totalling 45,907,938 shares, an increase of 16.9% from the July 14th total of 39,285,360 shares. Based on an average daily trading volume, of 4,970,113 shares, the short-interest ratio is currently 9.2 days.

Who are some of Teva Pharmaceutical Industries Limited's key competitors?

Who are Teva Pharmaceutical Industries Limited's key executives?

Teva Pharmaceutical Industries Limited's management team includes the folowing people:

  • Sol J. Barer, Chairman of the Board
  • Yitzhak Peterburg, Interim President and Chief Executive Officer
  • Eyal Desheh, Group Executive Vice President, Chief Financial Officer
  • Dipankar Bhattacharjee, President and Chief Executive Officer-Global Generic Medicines Group
  • Carlo de Notaristefani, President and Chief Executive Officer-Global Operations
  • Robert Koremans, President, Chief Executive Officer - Global Specialty Medicines
  • Iris Beck-Codner, Group Executive Vice President - Corporate Marketing & Communication
  • Hafrun Fridriksdottir, Executive Vice President, President of Global Generics R&D
  • Mark Sabag, Group Executive Vice President-Human Resources
  • David M. Stark, Group Executive Vice President-Chief Legal Officer

Who owns Teva Pharmaceutical Industries Limited stock?

Teva Pharmaceutical Industries Limited's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Capital Research Global Investors (7.51%), Franklin Resources Inc. (6.57%), FMR LLC (4.22%), Bank of New York Mellon Corp (1.79%), Northern Cross LLC (1.75%) and Nordea Investment Management AB (1.27%). View Institutional Ownership Trends for Teva Pharmaceutical Industries Limited.

Who sold Teva Pharmaceutical Industries Limited stock? Who is selling Teva Pharmaceutical Industries Limited stock?

Teva Pharmaceutical Industries Limited's stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, FIL Ltd, Janus Henderson Group PLC, South Texas Money Management Ltd., Great West Life Assurance Co. Can, Banque Pictet & Cie SA, Commerzbank Aktiengesellschaft FI and Airain ltd. View Insider Buying and Selling for Teva Pharmaceutical Industries Limited.

Who bought Teva Pharmaceutical Industries Limited stock? Who is buying Teva Pharmaceutical Industries Limited stock?

Teva Pharmaceutical Industries Limited's stock was bought by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Franklin Resources Inc., FMR LLC, Capital World Investors, Alliancebernstein L.P., Migdal Insurance & Financial Holdings Ltd., Northern Cross LLC and Polaris Capital Management LLC. View Insider Buying and Selling for Teva Pharmaceutical Industries Limited.

How do I buy Teva Pharmaceutical Industries Limited stock?

Shares of Teva Pharmaceutical Industries Limited can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Teva Pharmaceutical Industries Limited's stock price today?

One share of Teva Pharmaceutical Industries Limited stock can currently be purchased for approximately $17.10.


MarketBeat Community Rating for Teva Pharmaceutical Industries Limited (NYSE TEVA)
Community Ranking:  2.9 out of 5 ( )
Outperform Votes:  821 (Vote Outperform)
Underperform Votes:  594 (Vote Underperform)
Total Votes:  1,415
MarketBeat's community ratings are surveys of what our community members think about Teva Pharmaceutical Industries Limited and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Teva Pharmaceutical Industries Limited (NYSE:TEVA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 17 Hold Ratings, 7 Buy Ratings
Consensus Rating:Hold (Score: 2.24)
Consensus Price Target: $36.82 (115.33% upside)

Analysts' Ratings History for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/16/2017Citigroup Inc.DowngradeBuy -> Neutral$32.00 -> $19.00MediumView Rating Details
8/9/2017Deutsche Bank AGReiterated RatingBuy$43.00 -> $28.00HighView Rating Details
8/9/2017Jefferies Group LLCReiterated RatingHold$33.00 -> $26.00MediumView Rating Details
8/9/2017Cantor FitzgeraldReiterated RatingNeutral$31.00 -> $27.00HighView Rating Details
8/9/2017Credit Suisse GroupReiterated RatingOutperform$39.00HighView Rating Details
8/7/2017Barclays PLCLower Price TargetEqual Weight$38.00 -> $23.00HighView Rating Details
8/4/2017Piper Jaffray CompaniesReiterated RatingNeutral$28.00 -> $23.00HighView Rating Details
8/4/2017Sanford C. BernsteinDowngradeOutperform -> Market Perform$42.00 -> $28.00HighView Rating Details
8/4/2017Maxim GroupReiterated RatingHold$35.00HighView Rating Details
8/4/2017Cowen and CompanyDowngradeOutperform -> Market Perform$50.00 -> $30.00HighView Rating Details
8/4/2017Royal Bank Of CanadaDowngradeOutperform -> Underperform$37.00 -> $21.00N/AView Rating Details
8/3/2017CIBCReiterated RatingOutperform -> Market PerformHighView Rating Details
8/3/2017Oppenheimer Holdings, Inc.DowngradeOutperform -> Market Perform$41.00HighView Rating Details
8/2/2017MizuhoReiterated RatingHold$30.00HighView Rating Details
6/27/2017Wells Fargo & CompanyReiterated RatingHoldN/AView Rating Details
4/6/2017BTIG ResearchReiterated RatingNeutralLowView Rating Details
2/28/2017ArgusDowngradeBuy -> Hold$59.35 -> $31.90N/AView Rating Details
2/17/2017J P Morgan Chase & CoSet Price TargetHold$37.00N/AView Rating Details
1/31/2017Bank of America CorporationUpgradeNeutral -> BuyN/AView Rating Details
1/9/2017GabelliReiterated RatingBuyN/AView Rating Details
12/23/2016GuggenheimReiterated RatingBuy$80.00N/AView Rating Details
12/4/2016Morgan StanleyDowngradeOverweight -> Equal Weight$63.00 -> $42.00N/AView Rating Details
11/4/2016HSBC Holdings plcDowngradeBuy -> Hold$44.00 -> $66.00N/AView Rating Details
10/7/2016Leerink SwannSet Price TargetBuy$57.00N/AView Rating Details
9/29/2016OTR GlobalInitiated CoveragePositiveN/AView Rating Details
7/17/2016Goldman Sachs Group, Inc. (The)Lower Price Target$70.00 -> $60.00N/AView Rating Details
4/19/2016Canaccord GenuityReiterated RatingBuyN/AView Rating Details
3/2/2016NomuraReiterated RatingNeutral$73.00N/AView Rating Details
11/27/2015Berenberg BankLower Price TargetHold$72.00 -> $65.00N/AView Rating Details
(Data available from 8/18/2015 forward)

Earnings

Earnings History for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Earnings by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Earnings History by Quarter for Teva Pharmaceutical Industries Limited (NYSE TEVA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/21/2017        
8/3/20176/30/2017$1.06$0.99$5.72 billion$5.69 billionViewListenView Earnings Details
5/11/2017Q1 17$1.06$1.06$5.69 billion$5.63 billionViewN/AView Earnings Details
2/13/2017Q416$1.36$1.38$6.26 billion$6.25 billionViewN/AView Earnings Details
11/15/2016Q316$1.29$1.31$5.71 billion$5.56 billionViewN/AView Earnings Details
8/4/2016Q216$1.20$1.25$4.86 billion$5.00 billionViewN/AView Earnings Details
5/9/2016Q116$1.17$1.20$4.78 billion$4.81 billionViewN/AView Earnings Details
2/11/2016Q415$1.29$1.28$4.83 billion$4.88 billionViewListenView Earnings Details
10/29/2015Q315$1.28$1.35$4.75 billion$4.80 billionViewListenView Earnings Details
7/30/2015Q215$1.31$1.43$4.90 billion$4.97 billionViewListenView Earnings Details
4/30/2015Q115$1.26$1.36$4.84 billion$5.00 billionViewN/AView Earnings Details
2/5/2015Q414$1.31$1.31$5.17 billion$5.17 billionViewN/AView Earnings Details
10/30/2014Q314$1.23$1.32$5.09 billion$5.06 billionViewN/AView Earnings Details
7/31/2014Q214$1.21$1.23$5.08 billion$5.00 billionViewN/AView Earnings Details
5/1/2014Q114$1.22$1.22$5.11 million$5.00 billionViewN/AView Earnings Details
2/6/2014Q413$1.26$1.42$5.19 billion$5.40 billionViewN/AView Earnings Details
10/31/2013Q313$1.26$1.27$5.00 billion$5.06 billionViewN/AView Earnings Details
8/1/2013Q213$1.20$1.20$4.94 billion$4.90 billionViewN/AView Earnings Details
5/2/2013Q113$1.10$1.12$4.85 billion$4.90 billionViewN/AView Earnings Details
2/7/2013Q412$1.33$1.32$5.26 billion$5.20 billionViewN/AView Earnings Details
11/1/2012Q312$1.25$1.28$5.08 billion$5.00 billionViewN/AView Earnings Details
8/2/2012$1.28$1.28ViewN/AView Earnings Details
5/9/2012$1.44$1.47ViewN/AView Earnings Details
2/15/2012$1.58$1.59ViewN/AView Earnings Details
11/2/2011$1.22$1.25ViewN/AView Earnings Details
7/27/2011$1.08$1.10ViewN/AView Earnings Details
5/11/2011$1.03$1.04ViewN/AView Earnings Details
2/8/2011$1.28$1.25ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Current Year EPS Consensus Estimate: $4.19 EPS
Next Year EPS Consensus Estimate: $3.92 EPS

Dividends

Current Dividend Information for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Next Dividend:9/14/2017
Annual Dividend:$1.16
Dividend Yield:6.78%
Dividend Growth:2.10% (3 Year Average)
Payout Ratio:-18.95% (Trailing 12 Months of Earnings)
27.68% (Based on This Year's Estimates)
29.59% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Dividend History by Quarter for Teva Pharmaceutical Industries Limited (NYSE TEVA)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/7/2017quarterly$0.091.83%8/25/20178/29/20179/14/2017
5/11/2017quarterly$0.344.28%6/1/20176/5/20176/22/2017
2/13/2017quarterly$0.343.7%2/28/20173/2/20173/20/2017
11/15/2016quarterly$0.3412/1/201612/5/201612/20/2016
8/4/2016quarterly$0.348/18/20168/22/20169/8/2016
5/9/2016quarterly$0.345/20/20165/24/20166/7/2016
2/16/2016Quarterly$0.292/25/20162/29/20163/14/2016
10/29/2015quarterly$0.3411/13/201511/17/201512/3/2015
7/30/2015quarterly$0.348/18/20158/20/20159/3/2015
5/5/2015special$0.342.25%5/15/20155/19/20156/4/2015
2/5/2015quarterly$0.342.36%2/17/20152/19/20153/3/2015
10/31/2014special$0.322.43%11/13/201411/17/201412/2/2014
8/1/2014quarterly$0.352.61%8/19/20148/21/20149/4/2014
5/2/2014quarterly$0.352.77%5/16/20145/20/20146/2/2014
2/4/2014$0.342/20/20142/24/20143/10/2014
11/1/2013quarterly$0.333.51%11/18/201311/20/201312/2/2013
8/5/2013quarterly$0.323.34%8/16/20138/20/20139/3/2013
8/1/2013quarterly$0.328/20/20139/2/2013
5/6/2013special$0.323.28%5/16/20135/20/20136/3/2013
2/8/2013quarterly$0.313.21%2/19/20132/21/20133/7/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Latest Headlines for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Source:
DateHeadline
finance.yahoo.com logoValeant: Hard to Ignore the Positive Developments?
finance.yahoo.com - August 18 at 7:51 AM
investorplace.com logoBuy the Capitulation in Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock
investorplace.com - August 17 at 10:29 AM
finance.yahoo.com logoIsrael's Teva seeks partners for new drugs to relieve pressure
finance.yahoo.com - August 17 at 8:19 AM
finance.yahoo.com logoTeva Stock Tumbles Again, Citi Downgrades, Says 'We Have Been Wrong'
finance.yahoo.com - August 17 at 8:19 AM
finance.yahoo.com logo[$$] Generic drugmakers feel pinch as prices crumble
finance.yahoo.com - August 17 at 8:19 AM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Teva Pharmaceutical and Pluristem Therapeutics
finance.yahoo.com - August 17 at 8:19 AM
americanbankingnews.com logoTeva Pharmaceutical Industries Limited (TEVA) Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - August 16 at 11:23 AM
americanbankingnews.com logoTeva Pharmaceutical Industries Limited (TEVA) Stock Rating Lowered by Citigroup Inc.
www.americanbankingnews.com - August 16 at 8:56 AM
nasdaq.com logoFrancis Chou Buys Valeant Pharmaceuticals International Inc, Teva Pharmaceutical Industries, ...
www.nasdaq.com - August 16 at 8:11 AM
bloomberg.com logoTeva Cedes Spot as Israel's Biggest Firm in Blow to Prestige - Bloomberg
www.bloomberg.com - August 16 at 8:11 AM
seekingalpha.com logoTeva: On The Activist Radar - Seeking Alpha
seekingalpha.com - August 16 at 8:11 AM
investorplace.com logoTime to Start Buying Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock? - Investorplace.com
investorplace.com - August 16 at 8:11 AM
finance.yahoo.com logoTeva Must Clear Three Big Hurdles to Reclaim Its Perch
finance.yahoo.com - August 16 at 8:11 AM
finance.yahoo.com logoIsrael's Teva seeks partners to fund some drug development
finance.yahoo.com - August 16 at 8:11 AM
americanbankingnews.com logoTeva Pharmaceutical Industries Limited (TEVA) Expected to Announce Quarterly Sales of $5.63 Billion
www.americanbankingnews.com - August 16 at 2:54 AM
finance.yahoo.com logoTeva Cedes Spot as Israel's Biggest Firm in Blow to Prestige
finance.yahoo.com - August 15 at 7:36 AM
seekingalpha.com logoTeva - Fiddler Made A Goof? - Seeking Alpha
seekingalpha.com - August 14 at 6:14 AM
americanbankingnews.com logoTeva Pharmaceutical Industries Limited (TEVA) Sees Large Growth in Short Interest
www.americanbankingnews.com - August 14 at 3:04 AM
americanbankingnews.com logoTeva Pharmaceutical Industries Limited (TEVA) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - August 12 at 4:44 PM
finance.yahoo.com logo[$$] Two Ways to Cut Your Teva Losses
finance.yahoo.com - August 12 at 8:25 AM
finance.yahoo.com logoSolarEdge (SEDG) and Teva (TEVA) are Blowouts!
finance.yahoo.com - August 10 at 9:58 PM
finance.yahoo.com logoShort Sellers Hike Bets in Major Pharma
finance.yahoo.com - August 10 at 4:31 PM
finance.yahoo.com logoGeneric Drug Makers: The Worst Is Yet To Come
finance.yahoo.com - August 10 at 4:31 PM
finance.yahoo.com logoWhy Perrigo is Soaring
finance.yahoo.com - August 10 at 4:31 PM
finance.yahoo.com logoHere's why competitiveness in generic drug market is at r...
finance.yahoo.com - August 10 at 4:31 PM
finance.yahoo.com logoThe generic drug market ‘is at risk now’ from deflation, trade group says
finance.yahoo.com - August 10 at 4:31 PM
bloomberg.com logoTeva Ramps Up Sales With Medis, Respiratory Units - Bloomberg - Bloomberg
www.bloomberg.com - August 10 at 8:37 AM
bloomberg.com logoFed Up With Paying the Price for Teva's Woes, Workers Dig In - Bloomberg
www.bloomberg.com - August 10 at 8:37 AM
finance.yahoo.com logoFed Up With Paying the Price for Teva's Woes, Workers Dig In
finance.yahoo.com - August 10 at 8:37 AM
finance.yahoo.com logoIsrael's Stock Market Is Having a Disastrous Week
finance.yahoo.com - August 10 at 8:37 AM
benzinga.com logoA Long Road To Recovery For Teva Pharmaceuticals; Morgan Stanley Downgrades - Benzinga
www.benzinga.com - August 9 at 8:10 AM
finance.yahoo.com logoWith Teva Down 20%, Blaming FDA Policies
finance.yahoo.com - August 9 at 8:10 AM
seekingalpha.com logoTeva Pharmaceutical: An Opportunity Or A Falling Knife? - Seeking Alpha
seekingalpha.com - August 9 at 8:10 AM
finance.yahoo.com logoIsraeli Officials Ask Teva to Delay Planned Job Cuts
finance.yahoo.com - August 9 at 8:10 AM
seekingalpha.com logoIs Teva The Next Valeant? - Seeking Alpha
seekingalpha.com - August 9 at 8:10 AM
finance.yahoo.com logo[$$] Valeant/Teva: lost summer
finance.yahoo.com - August 9 at 8:10 AM
seekingalpha.com logoTeva's Shares Continue To Crater - Seeking Alpha
seekingalpha.com - August 9 at 8:10 AM
finance.yahoo.com logoTeva Sinks 40% as It Loses Top Rating from 5 Firms
finance.yahoo.com - August 9 at 8:10 AM
americanbankingnews.com logoTeva Pharmaceutical Industries Limited (NYSE:TEVA) Downgraded by BidaskClub
www.americanbankingnews.com - August 8 at 1:58 PM
fortune.com logoTeva Faces Rocky Path to Recovery After Debt | Fortune.com - Fortune
fortune.com - August 8 at 7:29 AM
marketwatch.com logoTeva's stock has tumbled over 8 sessions and Morgan Stanley says it could fall 16% more - MarketWatch
www.marketwatch.com - August 8 at 7:29 AM
seekingalpha.com logoTeva: A Sign Of Things To Come - Seeking Alpha
seekingalpha.com - August 8 at 7:29 AM
seekingalpha.com logoTeva urged to bring jobs home - Seeking Alpha
seekingalpha.com - August 8 at 7:29 AM
seekingalpha.com logoTeva Pharmaceuticals - A Deal Too Far? - Seeking Alpha
seekingalpha.com - August 8 at 7:29 AM
americanbankingnews.com logoTeva Pharmaceutical Industries Limited (NYSE:TEVA) Announces $0.09 Quarterly Dividend
www.americanbankingnews.com - August 7 at 6:34 PM
americanbankingnews.com logoBarclays PLC Cuts Teva Pharmaceutical Industries Limited (NYSE:TEVA) Price Target to $23.00
www.americanbankingnews.com - August 7 at 2:24 PM
bloomberg.com logoTeva's Trouble Was Predicted. Path to Recovery Not as Clear - Bloomberg
www.bloomberg.com - August 7 at 5:22 AM
finance.yahoo.com logoTeva's Trouble Was Predicted. Path to Recovery Not as Clear
finance.yahoo.com - August 7 at 5:22 AM
americanbankingnews.com logoTeva Pharmaceutical Industries Limited (TEVA) Downgraded by Royal Bank Of Canada to "Underperform"
www.americanbankingnews.com - August 7 at 12:56 AM
americanbankingnews.com logoTeva Pharmaceutical Industries Limited (TEVA) Rating Lowered to Neutral at Credit Suisse Group
www.americanbankingnews.com - August 6 at 11:34 PM

Social

Chart

Teva Pharmaceutical Industries Limited (TEVA) Chart for Friday, August, 18, 2017

This page was last updated on 8/18/2017 by MarketBeat.com Staff